ClinicalTrials.gg
RecruitingNCT01130545Updated Nov 12, 2026

Imaging Techniques in MRI

An observational study in Cardiac Risk Factors, Healthy and Healthy Volunteers, sponsored by National Institutes of Health Clinical Center (CC). Recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by National Institutes of Health Clinical Center (CC) · Observational

From the registry’s dates

  • Started Jun 2010; still recruiting 16 years 5 months later.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years to 100 Years
Sex
All
01

Study summary

Background:

- Magnetic resonance imaging (MRI) scans must be performed according to specified sets of parameters that provide optimal images of each organ and each area of the body. These scanning parameters are often specific to the institution or organization at which they are employed, and may also depend on the manufacturer of the MRI scanning equipment. Because MRI scanning equipment is always being updated and upgraded, researchers are interested in developing new and optimized scanning parameters for MRI scans.

Objectives:

- To improve current methods and develop new techniques for magnetic resonance imaging.

Eligibility:

  • Individuals 18 years of age and older who are either volunteers or current NIH protocol participants.
  • Participants must not have any medical history factors (e.g., extreme claustrophobia, history of metal implants) that would prevent them from receiving MRI scans.

Design:

  • Participants will have at least one MRI scan that will last from 20 minutes to 2 hours (most scans will last between 45 and 90 minutes). The total time commitment for most visits will be approximately 4 hours from start to finish.
  • Some MRI techniques require standard monitoring equipment or specific procedures during the scanning, such as an electrocardiogram.
  • Participants will have blood samples taken at the time of the scan. Some MRI studies will require the use of a contrast agent that will be administered during the scan.
  • Volunteers may be asked to return for additional MRI scans over the course of a few years. Follow-up scans may be done on the same part of the body or on different parts of the body. No more than one MRI scan will be performed in any 4-week period for this protocol.
Read the detailed description

Magnetic Resonance (MR) Imaging performed on volunteers will be used to develop and optimize techniques useful in the advancement of MRI technology.

02

Conditions studied

  • Cardiac Risk Factors
  • Healthy
  • Healthy Volunteers

Keywords

  • Healthy Volunteer
  • Magnetic Resonance Imaging
  • Gadolinium
  • Natural History
  • HV
03

In context

Lead sponsor

National Institutes of Health Clinical Center (CC) is the lead sponsor of 376 studies on the registry; 27 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 19 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Volunteers (maybe Volunteers, NIH employee and current NIH protocol participants)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A. Volunteer individuals

B. Lab Eligibility parameters (for contrast scans within 4 weeks of gadolinium injection):

C. Creatinine below upper normal limit

D. >= 60 mL/min/1.73m2

E. Age >= 60 or history of renal disease: test GFR within 1 week prior to contrast

F. Willing to travel to the NIH for follow-up visits.

G. 18 years old

H. Able to understand and sign

I. No MRI scan with gadolinium injection in the last 6 months under this protocol.

Exclusion criteria

EXCLUSION CRITERIA:

A. Implanted metal clips or wires of the type which may concentrate radiofrequency fields or cause tissue damages from twisting in a Magnetic field. Examples:

  • Aneurysm clip, implanted neural stimulator,
  • Implanted cardiac pacemaker, defibrillator, or certain other implanted electrical or metallic devices,
  • Cochlear implant, ocular foreign body (metal shavings),
  • Any implanted device (pumps, infusion devices, etc.),
  • Shrapnel injuries,
  • History of metal in head or eyes or other parts of the body.

B. Pregnant women

C. Paralyzed hemidiaphragm

D. Over 500 lbs and/or a body circumference that prevents the study subject from laying flat in the scanner

E. Surgery of uncertain type

F. Untreatable claustrophobia otherwise requiring anesthesia.

G. Any that the Physician identifies from the subject, MRI Safety Questionnaire, and/or History and Physical.

EXCLUSION FOR PARTICIPANTS FOR GADOLINIUM CONTRAST:

(Inclusive of the above exclusion criteria):

A. Allergy to gadolinium for scans using contrast; will be eligible for non-contrast scans.

B. Acute renal failure, renal transplant, dialysis and renal failure individuals ( \<60 mL/min/1.73m2 and/or clinically diagnosed).

C. Individuals with a history of liver transplant or severe liver disease.

D. Lactating women

E. Individuals with hemoglobinopathies or severe asthma.

F. Patient preference to not undergo intravenous line placement and/or receive gadolinium contrast. Contrast administration is optional and participants may still undergo a non-contrast study.

G. GBCA with an MRI scan in the last 6 months. This includes scan performed with GBCA at any outside institution and / or at the clinical center .In addition, they cannot have reached their maximum of 4 GBCA imaging studies under this protocol. They will be excluded from having a contrast enhanced MRI, but will not be excluded from the protocol for non-contrast MRI studies.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
1,000 participants (estimated)

Groups and cohorts

  • Volunteers

    Volunteers (maybe Volunteers, NIH employee and current NIH protocol participants)

06

What researchers measure

Primary outcomes

  1. To refine current methodology and develop new techniques for MRI

    To refine current methodology and develop new techniques for magnetic resonance imaging in the general population.

    Time frame: End of study

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
08

References and documents

Publications

  • Mattay VS, Weinberger DR, Barrios FA, Sobering GS, Kotrla KJ, van Gelderen P, Duyn JH, Sexton RH, Moonen CT, Frank JA. Brain mapping with functional MR imaging: comparison of gradient-echo--based exogenous and endogenous contrast techniques. Radiology. 1995 Mar;194(3):687-91. doi: 10.1148/radiology.194.3.7862963. PubMed 7862963 ↗
  • Perez-Rodriguez J, Lai S, Ehst BD, Fine DM, Bluemke DA. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases. Radiology. 2009 Feb;250(2):371-7. doi: 10.1148/radiol.2502080498. PubMed 19188312 ↗
  • Frank JA, Mattay VS, Duyn J, Sobering G, Barrios FA, Zigun J, Sexton R, Kwok P, Woo J, Moonen C, et al. Measurement of relative cerebral blood volume changes with visual stimulation by 'double-dose' gadopentetate-dimeglumine-enhanced dynamic magnetic resonance imaging. Invest Radiol. 1994 Jun;29 Suppl 2:S157-60. doi: 10.1097/00004424-199406001-00052. No abstract available. PubMed 7928216 ↗
  • Ahlman MA, Raman FS, Penzak SR, Pang J, Fan Z, Liu S, Gai N, Li D, Bluemke DA. Part 1 - Coronary angiography with gadofosveset trisodium: a prospective feasibility study evaluating injection techniques for steady-state imaging. BMC Cardiovasc Disord. 2015 Dec 22;15:177. doi: 10.1186/s12872-015-0176-0. PubMed 26695065 ↗
  • Raman FS, Nacif MS, Cater G, Gai N, Jones J, Li D, Sibley CT, Liu S, Bluemke DA. 3.0-T whole-heart coronary magnetic resonance angiography: comparison of gadobenate dimeglumine and gadofosveset trisodium. Int J Cardiovasc Imaging. 2013 Jun;29(5):1085-94. doi: 10.1007/s10554-013-0192-z. Epub 2013 Mar 21. PubMed 23515949 ↗

Individual participant data

Plan to share: Undecided — We are working on deciding if we want to share IPD.

09

Timeline

6 registry updates since Sep 25, 2026

Started Jun 2010 (actual).

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2010
First posted
May 26, 2010
StartActual
Jun 5, 2010
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: description
6 updates, last Nov 12, 2026
Show all 6 updates
  1. Nov 12, 2026
    Minor edits only
    + 1 other change: description
  2. Nov 9, 2026
    Minor edits only
    + 1 other change: description
  3. Nov 5, 2026
    Minor edits only
    + 1 other change: description
  4. Oct 16, 2026
    Minor edits only
    + 1 other change: description
  5. Oct 13, 2026
    Minor edits only
    + 1 other change: description
  6. Oct 8, 2026
    Minor edits only
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01130545
Responsible party
Sponsor
First posted
May 26, 2010
Start date
Jun 5, 2010
Last update
Nov 12, 2026

Study contacts

Tracy L Cropper, R.N.
Contact
tcropper@cc.nih.gov
(301) 402-6132
Bernadette A Redd, M.D.
Contact
bernadette.redd@nih.gov
(301) 215-0785
Bernadette A Redd, M.D.
principal investigator · National Institutes of Health Clinical Center (CC)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion